Last reviewed 2026-04-23 · How we verify

POLYGYNAX®

POLYGYNAX is a vaginal capsule containing a combination of antibiotics and antifungal agents that eliminates pathogenic bacteria and fungi in the vaginal tract.

POLYGYNAX is a vaginal capsule containing a combination of antibiotics and antifungal agents that eliminates pathogenic bacteria and fungi in the vaginal tract. Used for Vaginal infections caused by susceptible bacteria and Candida species, Non-specific vaginitis.

At a glance

Mechanism of action

The formulation combines neomycin sulfate, polymyxin B sulfate, and nystatin to provide broad-spectrum antimicrobial coverage against common vaginal pathogens. Neomycin and polymyxin B target bacterial cell walls and membranes, while nystatin disrupts fungal cell membranes by binding to ergosterol. This triple-agent approach addresses both bacterial and fungal vaginal infections simultaneously.

Approved indications

• Vaginal infections caused by susceptible bacteria and Candida species
• Non-specific vaginitis

Common side effects

• Local irritation or burning
• Allergic contact dermatitis
• Vulvovaginal discomfort

Key clinical trials

• Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• POLYGYNAX® CI brief — competitive landscape report
• POLYGYNAX® updates RSS · CI watch RSS
• Laboratoire Innotech International portfolio CI